Higher TNF-α/IL-33 and TNF-α/IL-4 ratios in responders suggest the predominance of proinflammatory potent stimulator TNF-α of anti-tumor immune response in NET patients who responded better to therapy and diminished immunosuppressive effect of IL-33 and IL-4. This evidence concerns the gene TNF and neoplasm.